Biotech & Pharma

StockWatch: Positive Phase III Data Sells Investors on Intellia

32 sec read319 views0 listens

Intellia Therapeutics' lead CRISPR therapy lonvoguran ziclumeran met three key secondary endpoints in Phase III trials for hereditary angioedema, with 62% of patients achieving sustained attack-free status versus 11% on placebo. The one-time gene-editing approach contrasts sharply with existing chronic therapies, demonstrating viable commercial demand for durable genetic interventions and validating in vivo CRISPR applications beyond research. Intellia expects to complete its rolling biologics license application by year-end, targeting FDA approval and launch in the first half of 2027.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

319

Home ownership dream broken? More Aussies are choosing to live together

Housing affordability challenges are driving more Australians to consider multigenerational living, with over half expressing openness to the idea. Research indicates a widespread belief that the traditional path to homeownership is broken for younge...

Ali Nemati

Biotech & Pharma6 days ago28 sec read

Pancreatic Cancer Cell Death Triggered by Caspase‑8 Blockade in Preclinical Models

Researchers at the University of Cologne’s Center for Molecular Medicine Cologne discovered that blocking caspase-8 can trigger cell death in KRAS-mutant pancreatic tumors, a common type of pancreatic cancer. This finding is significant because it id...

Ali Nemati

Real Estate & Home6 days ago25 sec read

iSelect data reveals priciest appliances to run this winter

New iSelect research has identified the most expensive household appliances to operate during winter, with reverse-cycle air conditioners costing an average of $1,111.91 and electric heaters at $246.37. This information is crucial for developers and ...

Ali Nemati

Biotech & PharmaJun 1524 sec read

ZoBio Introduces DNA-Encoded Library Service for Exploratory Drug Discovery Programs

ZoBio has launched a comprehensive DNA-Encoded Library (DEL) discovery service to aid in the identification of drug targets that are difficult or novel. This integrated platform combines multiple techniques, including protein production, biophysical ...

Ali Nemati

Biotech & PharmaJun 1230 sec read

Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model

Researchers at the University of Texas Medical Branch have developed a single-dose mRNA vaccine that provides full protection against the lethal Andes hantavirus in animal models. This breakthrough is critical for biotechnology professionals as it va...

Ali Nemati

StockWatch: Positive Phase III Data Sells Investors on Intellia

Related Articles

Home ownership dream broken? More Aussies are choosing to live together

Pancreatic Cancer Cell Death Triggered by Caspase‑8 Blockade in Preclinical Models

iSelect data reveals priciest appliances to run this winter

ZoBio Introduces DNA-Encoded Library Service for Exploratory Drug Discovery Programs

Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model